Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence

التفاصيل البيبلوغرافية
العنوان:	Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence
المؤلفون:	Harrington, K.J., Cohen, E.E.W., Soulières, D., Dinis, J., Licitra, L., Ahn, M.-J., Soria, A., Machiels, J.-P., Mach, N., Mehra, R., Burtness, B., Swaby, R.F., Lin, J., Ge, J., Lerman, N., Tourneau, C. Le
المصدر:	In Oral Oncology December 2023 147
قاعدة البيانات:	ScienceDirect

الوصف
تدمد:	13688375
DOI:	10.1016/j.oraloncology.2023.106587